Chemotherapy-induced mucositis: The role of mucin secretion and regulation, and the enteric nervous system

NeuroToxicology

Volumn 38, Issue , 2013, Pages 101-105

  Thorpe, Daniel ^a   Stringer, Andrea ^a,b   Butler, Ross ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Alimentary mucositis; Chemotherapy; Enteric nervous system; Mucins

Indexed keywords

AMINOGUANIDINE; ANTINEOPLASTIC AGENT; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; IRINOTECAN; METHOTREXATE; MUCIN; MUCIN 2; NEUROTRANSMITTER; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEASE ACTIVATION RECEPTOR 2; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ALIMENTARY MUCOSITIS; CANCER CHEMOTHERAPY; CYTOKINE RELEASE; DIGESTIVE SYSTEM INFLAMMATION; GASTROINTESTINAL MUCOSA; HUMAN; INTESTINE EPITHELIUM; INTESTINE INNERVATION; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SINGLE DRUG DOSE;

ALIMENTARY MUCOSITIS; CHEMOTHERAPY; ENTERIC NERVOUS SYSTEM; MUCINS;

ANTINEOPLASTIC AGENTS; DINOPROSTONE; ENTERIC NERVOUS SYSTEM; HUMANS; MODELS, BIOLOGICAL; MUCINS; MUCOSITIS; NITRIC OXIDE; RECEPTOR, PAR-2; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84881263451     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.06.007     Document Type: Review

References (73)

1. Allen A., Bell A., Mantle M., Pearson J.P. The structure and physiology of gastrointestinal mucus. Adv Exp Med Biol 1982, 144:115-133.
2. Baggott C. Biomarkers for mucositis assessment. Pediatr Blood Cancer 2009, 53:1169-1170.
3. Belai A., Boulos P.B., Robson T., Burnstock G. Neurochemical coding in the small intestine of patients with Crohn's disease. Gut 1997, 40:767-774.
4. Belai A., Burnstock G. Distribution and colocalization of nitric oxide synthase and calretinin in myenteric neurons of developing, aging, and Crohn's disease human small intestine. Dig Dis Sci 1999, 44:1579-1587.
5. Ben-Av P., Crofford L.J., Wilder R.L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372:83-87.
6. Bou-Hanna C., Berthon B., Combettes L., Claret M., Laboisse C.L. Role of calcium in carbachol- and neurotensin-induced mucin exocytosis in a human colonic goblet cell line and cross-talk with the cyclic AMP pathway. Biochem J 1994, 299(Pt 2):579-585.
7. Bowen J.M., Gibson R.J., Cummins A.G., Tyskin A., Keefe D.M. Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol 2007, 59:337-348.
8. Bowen J.M., Gibson R.J., Tsykin A., Stringer A.M., Logan R.M., Keefe D.M. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 2007, 121:1847-1856.
9. Branka J.E., Vallette G., Jarry A., Laboisse C.L. Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway. Biochem J 1997, 323(Pt 2):521-524.
10. Chandrasekharan B., Anitha M., Blatt R., Shahnavaz N., Kooby D., Staley C., et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil 2011, 23:131-138. e26.
11. Cho C.H. Current roles of nitric oxide in gastrointestinal disorders. J Physiol Paris 2001, 95:253-256.
12. de Koning B.A., Sluis M., Lindenbergh-Kortleve D.J., Velcich A., Pieters R., Buller H.A., et al. Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 2007, 210:144-152.
13. Deplancke B., Gaskins H.R. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr 2001, 73:1131S-1141S.
14. Dickson L., Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 2009, 121:294-316.
15. Elting L.S., Cooksley C., Chambers M., Cantor S.B., Manzullo E., Rubenstein E.B. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003, 98:1531-1539.
16. Fontaine N., Meslin J.C., Lory S., Andrieux C. Intestinal mucin distribution in the germ-free rat and in the heteroxenic rat harbouring a human bacterial flora: effect of inulin in the diet. Br J Nutr 1996, 75:881-892.
17. Fyfe M., Bergstrom M., Aspengren S., Peterson A. PAR-2 activation in intestinal epithelial cells potentiates interleukin-1beta-induced chemokine secretion via MAP kinase signaling pathways. Cytokine 2005, 31:358-367.
18. Gibson R.J., Bowen J.M., Inglis M.R., Cummins A.G., Keefe D.M. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003, 18:1095-1100.
19. Gibson R.J., Keefe D.M. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006, 14:890-900.
20. Gutierrez M.M., Alluisetti G.B., Olabe J.A., Amorebieta V.T. Nitrosation of N-methylhydroxylamine by nitroprusside. a kinetic and mechanistic study. Dalton Trans 2008, 5025-5030.
21. Jass J.R., Walsh M.D. Altered mucin expression in the gastrointestinal tract: a review. J Cell Mol Med 2001, 5:327-351.
22. Kase Y., Hayakawa T., Togashi Y., Kamataki T. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn J Pharmacol 1997, 75:399-405.
23. Kawabata A., Kinoshita M., Nishikawa H., Kuroda R., Nishida M., Araki H., et al. The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J Clin Invest 2001, 107:1443-1450.
24. Keefe D.M. Gastrointestinal mucositis: a new biological model. Support Care Cancer 2004, 12:6-9.
25. Keefe D.M., Brealey J., Goland G.J., Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000, 47:632-637.
26. Keefe D.M., Cummins A.G., Dale B.M., Kotasek D., Robb T.A., Sage R.E. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997, 92:385-389.
27. Keefe D.M., Schubert M.M., Elting L.S., Sonis S.T., Epstein J.B., Raber-Durlacher J.E., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007, 109:820-831.
28. Laburthe M., Augeron C., Rouyer-Fessard C., Roumagnac I., Maoret J.J., Grasset E., et al. Functional VIP receptors in the human mucus-secreting colonic epithelial cell line CL.16E. Am J Physiol 1989, 256:G443-G450.
29. Lalla R.V., Pilbeam C.C., Walsh S.J., Sonis S.T., Keefe D.M., Peterson D.E. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer 2010, 18:95-103.
30. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res Ther 2008, 10(Suppl. 2):S4.
31. Laszlo F., Whittle B.J., Moncada S. Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol 1994, 111:1309-1315.
32. Leitao R.F., Ribeiro R.A., Bellaguarda E.A., Macedo F.D., Silva L.R., Oria R.B., et al. Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 2007, 59:603-612.
33. Lima-Junior R.C., Figueiredo A.A., Freitas H.C., Melo M.L., Wong D.V., Leite C.A., et al. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 2012, 69:931-942.
34. Logan R.M., Gibson R.J., Bowen J.M., Stringer A.M., Sonis S.T., Keefe D.M. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008, 62:33-41.
35. Logan R.M., Stringer A.M., Bowen J.M., Gibson R.J., Sonis S.T., Keefe D.M. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008, 7:1139-1145.
36. Logan R.M., Stringer A.M., Bowen J.M., Yeoh A.S., Gibson R.J., Sonis S.T., et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007, 33:448-460.
37. Martin B., Lopez de Maturana R., Brenneman R., Walent T., Mattson M.P., Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med 2005, 7:3-36.
38. Mazumdar S., Das K.M. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992, 87:176-181.
39. Murthy K.S., Mahavadi S., Huang J., Zhou H., Sriwai W. Phosphorylation of GRK2 by PKA augments GRK2-mediated phosphorylation, internalization, and desensitization of VPAC2 receptors in smooth muscle. Am J Physiol Cell Physiol 2008, 294:C477-C487.
40. Nathan C. Inducible nitric oxide synthase: what difference does it make?. J Clin Invest 1997, 100:2417-2423.
41. Neutra M.R., O'Malley L.J., Specian R.D. Regulation of intestinal goblet cell secretion. II. A survey of potential secretagogues. Am J Physiol 1982, 242:G380-G387.
42. Phillips T.E., Stanley C.M., Wilson J. The effect of 16,16-dimethyl prostaglandin E2 on proliferation of an intestinal goblet cell line and its synthesis and secretion of mucin glycoproteins. Prostaglandins Leukot Essent Fatty Acids 1993, 48:423-428.
43. Pico J.L., Avila-Garavito A., Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998, 3:446-451.
44. Plaisancie P., Barcelo A., Moro F., Claustre J., Chayvialle J.A., Cuber J.C. Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 1998, 275:G1073-G1084.
45. Rhodes J.M. Colonic mucus and mucosal glycoproteins: the key to colitis and cancer?. Gut 1989, 30:1660-1666.
46. Robbe C., Capon C., Coddeville B., Michalski J.C. Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 2004, 384:307-316.
47. Rubenstein E.B., Peterson D.E., Schubert M., Keefe D., McGuire D., Epstein J., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004, 100:2026-2046.
48. Saegusa Y., Ichikawa T., Iwai T., Goso Y., Okayasu I., Ikezawa T., et al. Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 2008, 43:59-65.
49. Saltz L., Shimada Y., Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 1996, 32A(Suppl. 3):S24-S31.
50. Saltz L.B. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003, 1:35-46. discussion 38-41, 5-6.
51. Sandgren K., Lin Z., Fex Svenningsen A., Ekblad E. Vasoactive intestinal peptide and nitric oxide promote survival of adult rat myenteric neurons in culture. J Neurosci Res 2003, 72:595-602.
52. Savarese D.M., Hsieh C., Stewart F.M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997, 15:2981-2995.
53. Schneider J., Jehle E.C., Starlinger M.J., Neunlist M., Michel K., Hoppe S., et al. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease. Neurogastroenterol Motil 2001, 13:255-264.
54. Schulte-Bockholt A., Fink J.G., Meier D.A., Otterson M.F., Telford G.L., Hopp K., et al. Expression of mRNA for vasoactive intestinal peptide in normal human colon and during inflammation. Mol Cell Biochem 1995, 142:1-7.
55. Smirnov A., Perez R., Amit-Romach E., Sklan D., Uni Z. Mucin dynamics and microbial populations in chicken small intestine are changed by dietary probiotic and antibiotic growth promoter supplementation. J Nutr 2005, 135:187-192.
56. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 2004, 4:277-284.
57. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 2004, 20:11-15.
58. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004, 100:1995-2025.
59. Sonis S.T., O'Donnell K.E., Popat R., Bragdon C., Phelan S., Cocks D., et al. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 2004, 40:170-176.
60. Sonis S.T., Scherer J., Phelan S., Lucey C.A., Barron J.E., O'Donnell K.E., et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif 2002, 35(Suppl. 1):93-102.
61. Specian R.D., Oliver M.G. Functional biology of intestinal goblet cells. Am J Physiol 1991, 260:C183-C193.
62. Stringer A.M., Gibson R.J., Bowen J.M., Logan R.M., Ashton K., Yeoh A.S., et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 2009, 90:489-499.
63. Stringer A.M., Gibson R.J., Logan R.M., Bowen J.M., Yeoh A.S., Burns J., et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 2007, 232:96-106.
64. Stringer A.M., Gibson R.J., Logan R.M., Bowen J.M., Yeoh A.S., Hamilton J., et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009, 234:430-441.
65. Stringer A.M., Gibson R.J., Logan R.M., Bowen J.M., Yeoh A.S., Laurence J., et al. Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 2009, 64:123-132.
66. van Vliet M.J., Tissing W.J., Rings E.H., Koetse H.A., Stellaard F., Kamps W.A., et al. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 2009, 53:1188-1194.
67. Verburg M., Renes I.B., Meijer H.P., Taminiau J.A., Buller H.A., Einerhand A.W., et al. Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastroint Liver Physiol 2000, 279:G1037-G1047.
68. Wadler S., Benson A.B., Engelking C., Catalano R., Field M., Kornblau S.M., et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998, 16:3169-3178.
69. Wallace J.L., Miller M.J. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000, 119:512-520.
70. White C.M., Ji S., Cai H., Maudsley S., Martin B. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS & Neurol Disord Drug Targets 2010, 9:661-666.
71. Xu D.Z., Lu Q., Deitch E.A. Nitric oxide directly impairs intestinal barrier function. Shock 2002, 17:139-145.
72. Yeoh A.S., Bowen J.M., Gibson R.J., Keefe D.M. Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005, 63:1295-1303.
73. Yu X.J., Ren X.H., Xu Y.H., Chen L.M., Zhou C.L., Li C.Y. Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway. Neuropeptides 2010, 44:407-411.